CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, ...

Crispr ( CRSP) is said to have attracted takeover interest, according to traders, who cited a Betaville "uncooked' alert that ...

This biotech has already made impressive contributions to medicine, and it could make more. But does that make it a buy?

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its ...

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.16, representing a -2.56% change from its previous close.

Iovance Biotherapeutics and Intellia Therapeutics are two innovative small-cap biotechs. Both companies face serious issues ...

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

Dividends can get a bad rap. Some assume they are for retirees who need the income to pay their bills. Others believe that companies paying dividends don't offer meaningful growth prospects and aren't ...

CRISPR Therapeutics CRSP is expected to report third-quarter 2025 earnings later this week. The Zacks Consensus Estimate for quarterly sales is pegged at $6.71 million, while that for earnings is ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $62.56, moving -2.51% from the previous trading session. Elsewhere, the Dow saw a downswing of 0.16%, while the tech-heavy Nasdaq ...

Navitas (NASDAQ: NVTS) is surging after announcing a major partnership with Nvidia and posting a 771% gain in just six months. Despite declining revenue, investors are eyeing the stock's long-term ...